These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35020444)

  • 1. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
    Pan A; Reingold RE; Zhao JL; Moy A; Kraehenbuehl L; Dranitsaris G; McBride SM; Scher HI; Kollmeier MA; Xiao H; Rathkopf DE; Lacouture ME
    J Urol; 2022 May; 207(5):1010-1019. PubMed ID: 35020444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
    Uemura H; Koroki Y; Iwaki Y; Imanaka K; Kambara T; Lopez-Gitlitz A; Smith A; Uemura H
    BMC Urol; 2020 Sep; 20(1):139. PubMed ID: 32878613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
    Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
    Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maculopapular Drug Eruption Caused by Apalutamide: Case Report and Review of the Literature.
    Katayama H; Saeki H; Osada SI
    J Nippon Med Sch; 2022 Nov; 89(5):550-554. PubMed ID: 34526471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
    Yang Z; Shao Y; Huang H; Liu Y; Wang Z; Wang Y
    World J Urol; 2024 Mar; 42(1):171. PubMed ID: 38506974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
    Perez-Ruixo C; Ackaert O; Ouellet D; Chien C; Uemura H; Olmos D; Mainwaring P; Lee JY; Yu MK; Perez-Ruixo JJ; Smith MR; Small EJ
    Clin Cancer Res; 2020 Sep; 26(17):4460-4467. PubMed ID: 32561663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
    N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
    Schweizer MT; True L; Gulati R; Zhao Y; Ellis W; Schade G; Montgomery B; Goyal S; Nega K; Hakansson AK; Liu Y; Davicioni E; Pienta K; Nelson PS; Lin D; Wright J
    J Urol; 2023 Feb; 209(2):354-363. PubMed ID: 36621991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: Apalutamide-induced severe lethal cutaneous adverse effects in China.
    Wang Q; Cao H; Zhang X; Wu H; Tang Z
    Front Immunol; 2023; 14():1291564. PubMed ID: 38274795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
    Cremante M; Puglisi S; Gandini A; Guadagno A; Catalano F; Damassi A; Murianni V; Llaja Obispo MA; Banna GL; Buti S; Rebuzzi SE; Rescigno P; Fornarini G
    J Oncol Pharm Pract; 2023 Oct; 29(7):1748-1753. PubMed ID: 37282554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
    Wu J; Liu D; Offin M; Lezcano C; Torrisi JM; Brownstein S; Hyman DM; Gounder MM; Abida W; Drilon A; Harding JJ; Sullivan RJ; Janku F; Welsch D; Varterasian M; Groover A; Li BT; Lacouture ME
    Invest New Drugs; 2021 Jun; 39(3):785-795. PubMed ID: 33389388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
    Chung BH; Huang J; Ye ZQ; He DL; Uemura H; Arai G; Kim CS; Zhang YY; Koroki Y; Jeong S; Mundle S; Triantos S; McCarthy S; Chi KN; Ye DW
    Asian J Androl; 2022; 24(2):161-166. PubMed ID: 34259202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
    T'jollyn H; Ackaert O; Chien C; Lopez-Gitlitz A; McCarthy S; Ruixo CP; Karsh L; Chi K; Chowdhury S; Ruixo JP; Agarwal N
    Cancer Chemother Pharmacol; 2022 May; 89(5):629-641. PubMed ID: 35366072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.